Back to Search
Start Over
IFN Signaling and ICB Resistance: Time is on Tumor's Side.
- Source :
-
Trends in cancer [Trends Cancer] 2017 Mar; Vol. 3 (3), pp. 161-163. Date of Electronic Publication: 2017 Jan 30. - Publication Year :
- 2017
-
Abstract
- Activation of antitumor immunity upon immune checkpoint blockade (ICB) is one of the most promising strategies in cancer therapy. However, ICB resistance is frequently observed in cancer preclinical models and patients. A recent report in Cell reveals that sustained interferon (IFN) signaling confers tumor resistance to ICB by inducing the expression of an immunosuppressive multigenic program.<br /> (Copyright © 2017 Elsevier Inc. All rights reserved.)
- Subjects :
- Drug Resistance, Neoplasm genetics
Gene Expression Regulation, Neoplastic immunology
Genes, cdc drug effects
Humans
Interferons genetics
Neoplasms genetics
Neoplasms immunology
Signal Transduction immunology
Drug Resistance, Neoplasm immunology
Genes, cdc immunology
Interferons immunology
Neoplasms therapy
Subjects
Details
- Language :
- English
- ISSN :
- 2405-8025
- Volume :
- 3
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Trends in cancer
- Publication Type :
- Academic Journal
- Accession number :
- 28718428
- Full Text :
- https://doi.org/10.1016/j.trecan.2017.01.004